AbCellera BiologicsABCL -7.73%59 Cash Ratio is 10.67 as of Mar. 2026, which is 42% above its 10-year median of 7.49. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,385 Biotechnology companies, AbCellera Biologics ranks better than 81.88% on this metric.
AbCellera Biologics has a Cash Ratio of 10.67. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for AbCellera Biologics's Cash Ratio or its related term are showing as below:
ABCL'
s Cash Ratio Range Over the Past 10 Years
Min: 0.96 Med: 7.49 Max: 15.21
Current: 10.67
During the past 8 years, AbCellera Biologics's highest Cash Ratio was 15.21. The lowest was 0.96. And the median was 7.49.
ABCL's Cash Ratio is ranked better than 81.88% of 1385
companies
in the Biotechnology industry
Industry Median: 2.95
vs ABCL: 10.67
AbCellera Biologics (NAS:ABCL) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
AbCellera Biologics Cash Ratio Related Terms
AbCellera Biologics Cash Ratio Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AbCellera Biologics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (ABCL) has a Cash Ratio of 10.67 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on AbCellera Biologics and its competitors. This is 42% above median its historical median of 7.49. Over the past decade, AbCellera Biologics' Cash Ratio has ranged from 0.96 to 15.21. According to the industry distribution chart, AbCellera Biologics ranks #251 out of 1385 companies in the Biotechnology industry, placing it in the top 18.1%.
Is AbCellera Biologics' Cash Ratio too high?
AbCellera Biologics' current Cash Ratio of 10.67 is 42% above median its 10-year median of 7.49. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 15.21. The Biotechnology industry median Cash Ratio is 2.95. AbCellera Biologics' value of 10.67 is 261.7% above this industry median. Based on the distribution chart, AbCellera Biologics ranks #251 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Cash Ratio compare to AGIO and KOD?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #251 out of 1385 companies for Cash Ratio. This places AbCellera Biologics in the top 18% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.95. AbCellera Biologics' value of 10.67 is 261.7% above this benchmark. Historically, AbCellera Biologics' own Cash Ratio has ranged from 0.96 to 15.21 over the past decade. While the company's 10-year median is 7.49 vs. the industry median of 2.95, AbCellera Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current Cash Ratio of 10.67 is 261.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on AbCellera Biologics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Cash Ratio is 10.67, which is 42% above median its own 10-year median of 7.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.42, compared to a current price of $7.10 — trading 31% above its estimated fair value. The current Cash Ratio is 10.67, which is 42% above median its 10-year median of 7.49 and 261.7% above the Biotechnology industry median of 2.95. AbCellera Biologics' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Cash Ratio is 10.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $7.10 is trading 31% above its estimated GF Value™ of $5.42.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
Cash Ratio: 10.67 (42% above median its 10-year median of 7.49)
GF Value™: $5.42 vs. price of $7.10 (31% above fair value)
Industry Position: 261.7% above the Biotechnology median (#251 of 1385)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
